Somewhat Favorable News Coverage Somewhat Unlikely to Impact Perrigo (PRGO) Share Price

Media coverage about Perrigo (NYSE:PRGO) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Perrigo earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6469280521061 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s analysis:

How to Become a New Pot Stock Millionaire

A number of research firms recently commented on PRGO. Canaccord Genuity set a $105.00 target price on shares of Perrigo and gave the company a “buy” rating in a research report on Monday, March 26th. Oppenheimer set a $98.00 price objective on shares of Perrigo and gave the stock a “buy” rating in a research report on Monday, March 5th. Cantor Fitzgerald set a $107.00 price objective on shares of Perrigo and gave the stock a “buy” rating in a research report on Thursday, December 28th. Finally, Leerink Swann began coverage on shares of Perrigo in a research report on Tuesday, January 2nd. They set a “market perform” rating and a $90.00 price objective on the stock. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company’s stock. Perrigo has an average rating of “Hold” and a consensus price target of $91.88.

Shares of NYSE:PRGO traded down $1.73 during midday trading on Friday, hitting $81.99. The stock had a trading volume of 1,150,414 shares, compared to its average volume of 929,535. The company has a market cap of $11,790.59, a price-to-earnings ratio of 16.63, a PEG ratio of 2.08 and a beta of 0.76. The company has a quick ratio of 1.40, a current ratio of 1.96 and a debt-to-equity ratio of 0.53. Perrigo has a 1 year low of $63.68 and a 1 year high of $95.93.

Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, March 1st. The company reported $1.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.03. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.24 earnings per share. research analysts forecast that Perrigo will post 5.23 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 20th. Stockholders of record on Friday, March 2nd were issued a $0.19 dividend. This is an increase from Perrigo’s previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 1st. This represents a $0.76 annualized dividend and a dividend yield of 0.93%. Perrigo’s payout ratio is presently 15.42%.

In other news, CEO Uwe Roehrhoff bought 7,500 shares of the stock in a transaction dated Monday, March 5th. The shares were acquired at an average price of $81.85 per share, with a total value of $613,875.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,900 shares in the company, valued at $401,065. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by insiders.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Perrigo (PRGO) Share Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at

About Perrigo

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

Insider Buying and Selling by Quarter for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with's FREE daily email newsletter.

Leave a Reply